Related Experiment Video
Updated: Feb 19, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
17.2K
Genomic Markers in Prostate Cancer Decision Making
Vito Cucchiara1, Matthew R Cooperberg2, Marc Dall'Era1
1Department of Urology, School of Medicine, University of California, Davis, Sacramento, CA, USA.
European Urology
|November 14, 2017
Summary
Genomic biomarkers enhance prostate cancer (PCa) detection and risk assessment, improving treatment decisions. Further validation is needed for widespread clinical adoption of these advanced tools.
Area of Science:
- Genomic medicine
- Biomarker discovery
- Prostate cancer research
Background:
- Prostate-specific antigen (PSA) has limitations in specificity for prostate cancer (PCa) detection.
- Emerging genomic tools aim to improve PCa diagnosis and management.
- PCa is a heterogeneous disease requiring personalized approaches.
Purpose of the Study:
- To review the utility of genomic biomarkers in PCa.
- To assess their role in risk stratification, tumor differentiation, and therapy selection.
- To highlight advancements beyond traditional PSA testing.
Main Methods:
- PubMed literature search up to May 2017.
- Selection of recent original articles and clinical trials.
- Synthesis of evidence on genomic biomarker performance in PCa.
Main Results:
- Genomic biomarkers can identify high-risk individuals and differentiate tumor aggressiveness.
- Urine-based assays (SelectMDx, Mi-Prostate Score, ExoDx) aid biopsy decisions.
- Tools like Decipher and Oncotype DX improve risk stratification.
- Biomarkers (AR-V7) assist in selecting therapies for advanced or castration-resistant PCa.
Conclusions:
- Genomic biomarkers significantly improve PCa detection, prognosis, and risk evaluation.
- Clinical integration of these biomarkers requires further large-scale validation.
- Combining genomic data with clinical factors optimizes PCa management.
